qSTAR Medical aims to improve the lives of patients suffering from End Stage Renal Disease (ESRD) by developing an innovative vascular access device featuring STAR® Biomaterial.
qSTAR Medical SAS was established in late 2011 as a spinout of Healionics USA with the support of OSEO France to develop a needle-free percutaneous port system for improved, pain-free and cost-effective vascular access for hemodialysis (HD) therapy.
There are approximately 20 million patients worldwide who suffer from Chronic Kidney Disease (CKD). An estimated 10% of these patients (2m) have progressed to the severe loss of kidney function defined as End Stage Renal Disease (ESRD) which requires life-sustaining thrice-weekly or daily dialysis therapy. Vascular access is the "Achilles heel" of hemodialysis therapy due to its high complication rates. ESRD patients need and deserve better vascular access options – qSTAR was created to help.